---
title: "Nonmedical Switch from MabThera to Truxima Rituximab in Multiple Sclerosis: Effectiveness and Tole"
id: "medrxiv-21-effectiveness-and-tolerability-of-nonmedical-switching-from-originator-mabthera"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-21-effectiveness-and-tolerability-of-nonmedical-switching-from-originator-mabthera"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.01.26359456v1?rss=1"
published_at: "2026-08-03T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Nonmedical Switch from MabThera to Truxima Rituximab in Multiple Sclerosis: Effectiveness and Tole
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-21-effectiveness-and-tolerability-of-nonmedical-switching-from-originator-mabthera
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.01.26359456v1?rss=1)
- **Published At:** 2026-08-03T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This single-center retrospective cohort evaluated nonmedical switching from originator **MabThera** to biosimilar **Truxima** rituximab in 50 people with multiple sclerosis (pwMS) who had received at least two originator infusions and were followed for two years. - The study reports a decline in annualized relapse rate (ARR) from a pre-rituximab baseline of 0.45 (95% CI 0.28–0.68) to 0.02 (95% CI 0.00–0.13) on the originator and 0.00 (95% CI 0.00–0.05) on the biosimilar; comparison between originator and biosimilar periods showed p = 0.367. - In a paired imaging subset (n = 29), the proportion with active scans fell progressively (50.0%, 34.5%, 17.2%) with Cochran’s Q p = 0.040; no significant difference between originator and biosimilar periods by McNemar test (p = 0.227). - Peripheral **B-cell** depletion increased over time. - Tolerability findings indicated no patients discontinued the biosimilar during the two-year follow-up; all remained on Truxima at study end. - The authors conclude nonmedical switching to the biosimilar was associated with comparable clinical and radiological outcomes and acceptable tolerability in this cohort. - Study limitations inherent to the report: single-center, retrospective design, small sample size, and that MS is an off-label indication for rituximab — the paper is a preprint and not peer reviewed. - Administrative details: approved by King Saud Medical City IRB (H1RI-04-Apr23-04). Competing interests disclosed for one author; dataset available on reasonable request subject to institutional governance.
## Clinical Analysis & Structured Key Points
Effectiveness and Tolerability of Nonmedical Switching from Originator (MabThera) to Biosimilar (Truxima) Rituximab in People with Multiple Sclerosis: A Tertiary Single-Center Observational Study | medRxiv Skip to main content Effectiveness and Tolerability of Nonmedical Switching from Originator (MabThera) to Biosimilar (Truxima) Rituximab in People with Multiple Sclerosis: A Tertiary Single-Center Observational Study View ORCID Profile Ahmed H. Althobaiti , Afnan A Alnughaimish , Saif S Alqahtani , View ORCID Profile Fahad Aldosari doi: https://doi.org/10.64898/2026.08.01.26359456 Ahmed H. Althobaiti 1 King Saud Medical City, Neurology Department; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Ahmed H. Althobaiti For correspondence: ahmed{at}ahmedalthobaiti.bio Afnan A Alnughaimish 2 Dr Sulaiman AlHabib Medical Center, Neurology Department; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Saif S Alqahtani 3 Riyadh Regional Laboratory, Immunology and Flowcytometry Department; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Fahad Aldosari 4 King Saud Medical City, Department of Pharmacy Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Fahad Aldosari Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Background: Rituximab is used off-label for multiple sclerosis (MS), and biosimilar substitution raises a distinct extrapolation challenge, as MS is not an approved indication for the reference product. Real-world nonmedical switching data inform biosimilar appropriateness decisions by clinicians, societies, and payers. Objective: To report the effectiveness and tolerability of nonmedical switching from originator (MabThera) to biosimilar rituximab (Truxima) in people with MS (pwMS). Methods: A retrospective, single-center observational cohort study of 50 pwMS switched after at least two originator infusions, followed for two years. Results: Annualized relapse rate declined from 0.45 (95% CI 0.28 - 0.68) prerituximab to 0.02 (95% CI 0.00 - 0.13) on originator and 0.00 (95% CI 0.00 - 0.05) on biosimilar (p = 0.367 between products). In paired imaging analysis (n = 29), the proportion with active scans declined progressively (50.0%, 34.5%, 17.2%; Cochrans Q, p = 0.040), with no difference between the originator and biosimilar periods (McNemar, p = 0.227). B-cell depletion deepened progressively. All patients remained on biosimilar through the end of follow-up. Conclusion: Nonmedical switching from originator to biosimilar rituximab was associated with comparable clinical and radiological outcomes, supporting its use in pwMS without concern for inferior efficacy or diminished tolerability. Competing Interest Statement Ahmed H. Althobaiti has received speaker/advisory fees or travel support from: AstraZeneca, Biogen, Biologix, Hikma, Merck, Neuraxpharm Middle East, Novartis, Roche, Sandoz, Sanofi, Sudair-Pharm. All other authors declare no conflict of interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was approved by the King Saud Medical City Institutional Review Board (approval number: H1RI-04-Apr23-04). Patient informed consent was not required, as data were collected exclusively from routine clinical records with no patient contact initiated for research purposes. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The dataset supporting the conclusions of this article is available from the corresponding author upon reasonable request and subject to institutional data governance approval. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Back to top Previous Next Posted August 03, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Effectiveness and Tolerability of Nonmedical Switching from Originator (MabThera) to Biosimilar (Truxima) Rituximab in People with Multiple Sclerosis: A Tertiary Single-Center Observational Study Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Effectiveness and Tolerability of Nonmedical Switching from Originator (MabThera) to Biosimilar (Truxima) Rituximab in People with Multiple Sclerosis: A Tertiary Single-Center Observational Study Ahmed H. Althobaiti , Afnan A Alnughaimish , Saif S Alqahtani , Fahad Aldosari medRxiv 2026.08.01.26359456; doi: https://doi.org/10.64898/2026.08.01.26359456 Share This Article: Copy Citation Tools Effectiveness and Tolerability of Nonmedical Switching from Originator (MabThera) to Biosimilar (Truxima) Rituximab in People with Multiple Sclerosis: A Tertiary Single-Center Observational Study Ahmed H. Althobaiti , Afnan A Alnughaimish , Saif S Alqahtani , Fahad Aldosari medRxiv 2026.08.01.26359456; doi: https://doi.org/10.64898/2026.08.01.26359456 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (594) Allergy and Immunology (888) Anesthesia (322) Cardiovascular Medicine (4683) Dentistry and Oral Medicine (466) Dermatology (402) Emergency Medicine (631) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1593) Epidemiology (15649) Forensic Medicine (32) Gastroenterology (1179) Genetic and Genomic Medicine (6880) Geriatric Medicine (715) Health Economics (1034) Health Informatics (4855) Health Policy (1412) Health Systems and Quality Improvement (1699) Hematology (568) HIV/AIDS (1306) Infectious Diseases (except HIV/AIDS) (16146) Intensive Care and Critical Care Medicine (1145) Medical Education (650) Medical Ethics (148) Nephrology (705) Neurology (7032) Nursing (357) Nutrition (1057) Obstetrics and Gynecology (1206) Occupational and Environmental Health (988) Oncology (3510) Ophthalmology (1015) Orthopedics (381) Otolaryngology (433) Pain Medicine (455) Palliative Medicine (135) Pathology (695) Pediatrics (1752) Pharmacology and Therapeutics (724) Primary Care Research (751) Psychiatry and Clinical Psychology (5724) Public and Global Health (9552) Radiology and Imaging (2326) Rehabilitation Medicine and Physical Therapy (1406) Respiratory Medicine (1228) Rheumatology (628) Sexual and Reproductive Health (756) Sports Medicine (567) Surgery (750) Toxicology (105) Transplantation (299) Urology (278)
## Related Clinical Research

- [Concurrent Neurofibromatosis Type 1 and Multiple Sclerosis in a Child: MRI, CSF, and 2024 Criteria](https://medichelpline.com/clinical-feed/pubmed-42485588.md) (DOI: 10.1212/WNL.0000000000218240)
- [Rituximab in Autoimmune Myasthenic Syndromes: Real‑World Outcomes in MG and LEMS](https://medichelpline.com/clinical-feed/medrxiv-12-rituximab-for-autoimmune-myasthenic-syndromes-a-retrospective-cohort-study-in.md)
- [Efgartigimod for refractory thymoma-associated overlap of stiff-person syndrome and myasthenia gra](https://medichelpline.com/clinical-feed/frontiers-in-immunology-3-case-report-efgartigimod-a-beacon-of-hope-for-overlapping-stiff-person-syndrome.md)
- [2026 Stroke Rehabilitation Guideline: Start Early and Address Physical, Cognitive, and Mental Heal](https://medichelpline.com/clinical-feed/medical-news-today-0-stroke-rehab-guidelines-emphasize-early-support-for-physical-cognitive-and.md)
- [Childhood Maltreatment, Poor Sleep, and Fear of Relapse in Multiple Sclerosis: A Clinical Summary](https://medichelpline.com/clinical-feed/medrxiv-1-exploring-the-negative-triad-of-childhood-maltreatment-fear-of-relapse-and-low.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.